Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 3/20 | 0.40 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CD38 | P28907 | 2/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | MDM4 | O15151 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL983581 | 0.93 | BTK (0.40) | BTKHTR4TSHRHPGDSTBK1 | |
| SCHEMBL984910 | 0.92 | HPGDS (0.45) | BTKHTR4TSHRCD38HPGDS | |
| SCHEMBL982565 | 0.91 | HPGDS (0.39) | HTR4TSHRCD38HPGDSMCHR1 | |
| SCHEMBL981845 | 0.89 | KDM4E (0.43) | BTKHTR4CD38KMT2AMEN1 | |
| SCHEMBL984117 | 0.89 | KDM4E (0.43) | BTKHTR4CD38KMT2AMEN1 | |
| SCHEMBL986466 | 0.89 | HTR4 (0.36) | BTKHTR4TSHRCD38HPGDS | |
| SCHEMBL981665 | 0.89 | ALDH1A1 (0.42) | BTKKMT2AMEN1 | |
| SCHEMBL984754 | 0.88 | HTR4 (0.40) | BTKHTR4CD38KMT2AMEN1 | |
| SCHEMBL981844 | 0.88 | HTR4 (0.41) | BTKHTR4CD38HPGDS | |
| SCHEMBL981879 | 0.88 | HTR4 (0.51) | BTKHTR4CD38HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101959890-B | Pyrrolopyrimidine carboxamides | NYCOMED GMBH | 2013-10-30 | — | — | CN | claimed |
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | claimed |
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE3A, PDE2A | BTK 1977/4885HTR4 1818/4885TSHR 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.